Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Greed Is Good who wrote (193)	12/21/1997 1:02:00 PM
From: Mark B. Martell, CCM	Respond to of 1510

Gentlepersons, My guess why the stock has gone down is some recent profit taking and "buying on rumor, selling on news". Like myself. I bought IMNR back in March hoping for a run up through November based on Remune's progress. The company seemed to point us towards November for commercial viability of Remune. The stock had run from $6-8 to $11-14 per share on this hope. When the stock got to $13 and IMNR told us that Remune was 7 months away (May) from having a more definitive view of Remune's success, it appeared to me to be a good time for some profit taking. Hopefully they won't strike some sort of licensing deal before the mid/end first quarter so that I can buy back in before the next run up through May. I'll be watching this one closely. I see great things in the pipeline with this company...... Mark

To: Greed Is Good who wrote (193)	12/22/1997 5:11:00 AM
From: Harry D. Kramer	Read Replies (1) \| Respond to of 1510

Hi Greed, I am a long-term investor in IMNR and I don't care too much about short-term movements, especially at the end of December. This time of the year has never been an easy call. I have no new information regarding IMNR that would change my view on the company's future. I agree with Mark that the last few days were normal profit taking, although I don't buy the reason. The fact that we won't hear any interim results from the Remune trial until late in the second quarter 1998 is not new. This has been in the market for quite some time. IMO, last weeks drop was also related to options expiration. I agree with you that we can find many reasons to overweight the biotech sector right now (see my ATIS post #1226), but the market doesn't really care about it, as we have seen in the last few days. Uncertainty is high and will remain high for the next few weeks, and in such an environment Wall Street will stay away from the high-risk stuff. And biotech as a group is still sky-high risk! Harry